UNLABELLED: HIV-1 assembles at the plasma membrane of virus-producing cells as an immature, noninfectious particle. Processing of the Gag and Gag-Pol polyproteins by the viral protease (PR) activates the viral enzymes and results in dramatic structural rearrangements within the virion--termed maturation--that are a prerequisite for infectivity. Despite its fundamental importance for viral replication, little is currently known about the regulation of proteolysis and about the dynamics and structural intermediates of maturation. This is due mainly to the fact that HIV-1 release and maturation occur asynchronously both at the level of individual cells and at the level of particle release from a single cell. Here, we report a method to synchronize HIV-1 proteolysis in vitro based on protease inhibitor (PI) washout from purified immature virions, thereby temporally uncoupling virus assembly and maturation. Drug washout resulted in the induction of proteolysis with cleavage efficiencies correlating with the off-rate of the respective PR-PI complex. Proteolysis of Gag was nearly complete and yielded the correct products with an optimal half-life (t(1/2)) of ~5 h, but viral infectivity was not recovered. Failure to gain infectivity following PI washout may be explained by the observed formation of aberrant viral capsids and/or by pronounced defects in processing of the reverse transcriptase (RT) heterodimer associated with a lack of RT activity. Based on our results, we hypothesize that both the polyprotein processing dynamics and the tight temporal coupling of immature particle assembly and PR activation are essential for correct polyprotein processing and morphological maturation and thus for HIV-1 infectivity. IMPORTANCE: Cleavage of the Gag and Gag-Pol HIV-1 polyproteins into their functional subunits by the viral protease activates the viral enzymes and causes major structural rearrangements essential for HIV-1 infectivity. This proteolytic maturation occurs concomitant with virus release, and investigation of its dynamics is hampered by the fact that virus populations in tissue culture contain particles at all stages of assembly and maturation. Here, we developed an inhibitor washout strategy to synchronize activation of protease in wild-type virus. We demonstrated that nearly complete Gag processing and resolution of the immature virus architecture are accomplished under optimized conditions. Nevertheless, most of the resulting particles displayed irregular morphologies, Gag-Pol processing was not faithfully reconstituted, and infectivity was not recovered. These data show that HIV-1 maturation is sensitive to the dynamics of processing and also that a tight temporal link between virus assembly and PR activation is required for correct polyprotein processing.

Department of Biochemistry Faculty of Science Charles University Prague Prague Czech Republic

Department of Infectious Diseases Virology University Hospital Heidelberg Heidelberg Germany

Department of Infectious Diseases Virology University Hospital Heidelberg Heidelberg Germany Molecular Medicine Partnership Unit Heidelberg Germany

Structural and Computational Biology Unit European Molecular Biology Laboratory Heidelberg Germany Molecular Medicine Partnership Unit Heidelberg Germany

Zobrazit více v PubMed

Briggs JA, Krausslich HG. 2011. The molecular architecture of HIV. J. Mol. Biol. 410:491–500. 10.1016/j.jmb.2011.04.021. PubMed DOI

Ganser-Pornillos BK, Yeager M, Pornillos O. 2012. Assembly and architecture of HIV. Adv. Exp. Med. Biol. 726:441–465. 10.1007/978-1-4614-0980-9_20. PubMed DOI PMC

Sundquist WI, Krausslich HG. 2012. HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med. 2:a006924. 10.1101/cshperspect.a006924. PubMed DOI PMC

Anderson J, Schiffer C, Lee SK, Swanstrom R. 2009. Viral protease inhibitors. Handb. Exp. Pharmacol. 2009(189):85–110. 10.1007/978-3-540-79086-0_4. PubMed DOI PMC

Pokorna J, Machala L, Rezacova P, Konvalinka J. 2009. Current and novel inhibitors of HIV protease. Viruses 1:1209–1239. 10.3390/v1031209. PubMed DOI PMC

Wensing AM, van Maarseveen NM, Nijhuis M. 2010. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 85:59–74. 10.1016/j.antiviral.2009.10.003. PubMed DOI

Benjamin J, Ganser-Pornillos BK, Tivol WF, Sundquist WI, Jensen GJ. 2005. Three-dimensional structure of HIV-1 virus-like particles by electron cryotomography. J. Mol. Biol. 346:577–588. 10.1016/j.jmb.2004.11.064. PubMed DOI PMC

Briggs JA, Riches JD, Glass B, Bartonova V, Zanetti G, Krausslich HG. 2009. Structure and assembly of immature HIV. Proc. Natl. Acad. Sci. U. S. A. 106:11090–11095. 10.1073/pnas.0903535106. PubMed DOI PMC

Briggs JA, Grunewald K, Glass B, Forster F, Krausslich HG, Fuller SD. 2006. The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. Structure 14:15–20. 10.1016/j.str.2005.09.010. PubMed DOI

Briggs JA, Wilk T, Welker R, Krausslich HG, Fuller SD. 2003. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22:1707–1715. 10.1093/emboj/cdg143. PubMed DOI PMC

Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, Sundquist WI, Jensen GJ. 2007. Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J. 26:2218–2226. 10.1038/sj.emboj.7601664. PubMed DOI PMC

Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI. 1999. Assembly and analysis of conical models for the HIV-1 core. Science 283:80–83. 10.1126/science.283.5398.80. PubMed DOI

Li S, Hill CP, Sundquist WI, Finch JT. 2000. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407:409–413. 10.1038/35030177. PubMed DOI

Bharat TA, Davey NE, Ulbrich P, Riches JD, de Marco A, Rumlova M, Sachse C, Ruml T, Briggs JA. 2012. Structure of the immature retroviral capsid at 8 A resolution by cryo-electron microscopy. Nature 487:385–389. 10.1038/nature11169. PubMed DOI

Lanman J, Lam TT, Emmett MR, Marshall AG, Sakalian M, Prevelige PE., Jr 2004. Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange. Nat. Struct. Mol. Biol. 11:676–677. 10.1038/nsmb790. PubMed DOI

Krausslich HG. 1991. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc. Natl. Acad. Sci. U. S. A. 88:3213–3217. 10.1073/pnas.88.8.3213. PubMed DOI PMC

Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe DE, Tritch R, Hutchison CA, III, Loeb DD, Swanstrom R. 1989. Cleavage of HIV-1 Gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Human Retroviruses 5:577–591. 10.1089/aid.1989.5.577. PubMed DOI

Pettit SC, Lindquist JN, Kaplan AH, Swanstrom R. 2005. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2:66. 10.1186/1742-4690-2-66. PubMed DOI PMC

Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, Swanstrom R. 1994. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:8017–8027. PubMed PMC

Coren LV, Thomas JA, Chertova E, Sowder RC, II, Gagliardi TD, Gorelick RJ, Ott DE. 2007. Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J. Virol. 81:10047–10054. 10.1128/JVI.02496-06. PubMed DOI PMC

de Marco A, Heuser AM, Glass B, Krausslich HG, Muller B, Briggs JA. 2012. Role of the SP2 domain and its proteolytic cleavage in HIV-1 structural maturation and infectivity. J. Virol. 86:13708–13716. 10.1128/JVI.01704-12. PubMed DOI PMC

Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG. 1998. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72:2846–2854. PubMed PMC

Lee SK, Potempa M, Swanstrom R. 2012. The choreography of HIV-1 proteolytic processing and virion assembly. J. Biol. Chem. 287:40867–40874. 10.1074/jbc.R112.399444. PubMed DOI PMC

Chojnacki J, Muller B. 2013. Investigation of HIV-1 assembly and release using modern fluorescence imaging techniques. Traffic 14:15–24. 10.1111/tra.12006. PubMed DOI

Lata R, Conway JF, Cheng N, Duda RL, Hendrix RW, Wikoff WR, Johnson JE, Tsuruta H, Steven AC. 2000. Maturation dynamics of a viral capsid: visualization of transitional intermediate states. Cell 100:253–263. 10.1016/S0092-8674(00)81563-9. PubMed DOI

Steven AC, Heymann JB, Cheng N, Trus BL, Conway JF. 2005. Virus maturation: dynamics and mechanism of a stabilizing structural transition that leads to infectivity. Curr. Opin. Struct. Biol. 15:227–236. 10.1016/j.sbi.2005.03.008. PubMed DOI PMC

Manchester M, Loeb DD, Everitt L, Moody M, Hutchison CA, III, Swanstrom R. 1991. Analysis of temperature-sensitive mutants of the HIV-1 protease. Adv. Exp. Med. Biol. 306:493–497. 10.1007/978-1-4684-6012-4_63. PubMed DOI

Konvalinka J. 1994. Structural and molecular biology of protease function and inhibition. Keystone Symposium. Santa Fe, New Mexico, March 5–12, 1994. Abstracts. J. Cell. Biochem. Suppl. 18D:117–177. PubMed

Sluis-Cremer N, Arion D, Abram ME, Parniak MA. 2004. Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. Int. J. Biochem. Cell Biol. 36:1836–1847. 10.1016/j.biocel.2004.02.020. PubMed DOI

Adachi A, Koenig S, Gendelman HE, Daugherty D, Gattoni-Celli S, Fauci AS, Martin MA. 1987. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61:209–213. PubMed PMC

Lampe M, Briggs JA, Endress T, Glass B, Riegelsberger S, Krausslich HG, Lamb DC, Brauchle C, Muller B. 2007. Double-labeled HIV-1 particles for study of virus-cell interaction. Virology 360:92–104. 10.1016/j.virol.2006.10.005. PubMed DOI

Dettenhofer M, Yu XF. 1999. Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. J. Virol. 73:4696–4704. PubMed PMC

Pizzato M, Erlwein O, Bonsall D, Kaye S, Muir D, McClure MO. 2009. A one-step SYBR green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. J. Virol. Methods 156:1–7. 10.1016/j.jviromet.2008.10.012. PubMed DOI

Mastronarde DN. 2005. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152:36–51. 10.1016/j.jsb.2005.07.007. PubMed DOI

Kremer JR, Mastronarde DN, McIntosh JR. 1996. Computer visualization of three-dimensional image data using IMOD. J. Struct. Biol. 116:71–76. 10.1006/jsbi.1996.0013. PubMed DOI

Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K. 2007. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J. Virol. 81:13845–13851. 10.1128/JVI.01184-07. PubMed DOI PMC

Markgren PO, Schaal W, Hamalainen M, Karlen A, Hallberg A, Samuelsson B, Danielson UH. 2002. Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J. Med. Chem. 45:5430–5439. 10.1021/jm0208370. PubMed DOI

Shuman CF, Hamalainen MD, Danielson UH. 2004. Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. J. Mol. Recognit. 17:106–119. 10.1002/jmr.655. PubMed DOI

Darke PL, Leu CT, Davis LJ, Heimbach JC, Diehl RE, Hill WS, Dixon RA, Sigal IS. 1989. Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. J. Biol. Chem. 264:2307–2312. PubMed

Hyland LJ, Tomaszek TA, Jr, Meek TD. 1991. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 30:8454–8463. PubMed

Polgar L, Szeltner Z, Boros I. 1994. Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease. Biochemistry 33:9351–9357. 10.1021/bi00197a040. PubMed DOI

Lee SK, Potempa M, Kolli M, Ozen A, Schiffer CA, Swanstrom R. 2012. Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. J. Biol. Chem. 287:13279–13290. 10.1074/jbc.M112.339374. PubMed DOI PMC

Konvalinka J, Heuser AM, Hruskova-Heidingsfeldova O, Vogt VM, Sedlacek J, Strop P, Krausslich HG. 1995. Proteolytic processing of particle-associated retroviral polyproteins by homologous and heterologous viral proteinases. Eur. J. Biochem. 228:191–198. 10.1111/j.1432-1033.1995.tb20249.x. PubMed DOI

Muller B, Anders M, Akiyama H, Welsch S, Glass B, Nikovics K, Clavel F, Tervo HM, Keppler OT, Krausslich HG. 2009. HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J. Biol. Chem. 284:29692–29703. 10.1074/jbc.M109.027144. PubMed DOI PMC

Jolly C, Welsch S, Michor S, Sattentau QJ. 2011. The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse. PLoS Pathog. 7:e1002226. 10.1371/journal.ppat.1002226. PubMed DOI PMC

Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, Sattentau QJ. 2010. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 84:3516–3527. 10.1128/JVI.02651-09. PubMed DOI PMC

Konnyu B, Sadiq SK, Turanyi T, Hirmondo R, Muller B, Krausslich HG, Coveney PV, Muller V. 2013. Gag-Pol processing during HIV-1 virion maturation: a systems biology approach. PLoS Comput. Biol. 9:e1003103. 10.1371/journal.pcbi.1003103. PubMed DOI PMC

Dale BM, McNerney GP, Thompson DL, Hubner W, de Los Reyes K, Chuang FY, Huser T, Chen BK. 2011. Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion. Cell Host Microbe 10:551–562. 10.1016/j.chom.2011.10.015. PubMed DOI PMC

Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Krausslich HG, Brun-Vezinet F, Boucher CA. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4:e36. 10.1371/journal.pmed.0040036. PubMed DOI PMC

Lee SK, Harris J, Swanstrom R. 2009. A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J. Virol. 83:8536–8543. 10.1128/JVI.00317-09. PubMed DOI PMC

Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R. 1995. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J. Virol. 69:2729–2736. PubMed PMC

Engelman A. 1999. In vivo analysis of retroviral integrase structure and function. Adv. Virus Res. 52:411–426. 10.1016/S0065-3527(08)60309-7. PubMed DOI

Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, Koh Y, Wang W, Ballandras-Colas A, Patel PA, Fuchs JR, Kvaratskhelia M, Engelman A. 2013. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc. Natl. Acad. Sci. U. S. A. 110:8690–8695. 10.1073/pnas.1300703110. PubMed DOI PMC

Balakrishnan M, Yant SR, Tsai L, O'Sullivan C, Bam RA, Tsai A, Niedziela-Majka A, Stray KM, Sakowicz R, Cihlar T. 2013. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One 8:e74163. 10.1371/journal.pone.0074163. PubMed DOI PMC

Desimmie BA, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C, Thys W, Vets S, Van Remoortel B, Hofkens J, De Rijck J, Hendrix J, Bannert N, Gijsbers R, Christ F, Debyser Z. 2013. LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology 10:57. 10.1186/1742-4690-10-57. PubMed DOI PMC

Jurado KA, Engelman A. 2013. Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors. Exp. Rev. Mol. Med. 15:e14. 10.1017/erm.2013.15. PubMed DOI PMC

Abram ME, Parniak MA. 2005. Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. J. Virol. 79:11952–11961. 10.1128/JVI.79.18.11952-11961.2005. PubMed DOI PMC

Dunn LL, McWilliams MJ, Das K, Arnold E, Hughes SH. 2009. Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions. J. Virol. 83:12336–12344. 10.1128/JVI.00676-09. PubMed DOI PMC

Restle T, Muller B, Goody RS. 1990. Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J. Biol. Chem. 265:8986–8988. PubMed

The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery

Viral proteases as therapeutic targets

Precursors of Viral Proteases as Distinct Drug Targets

Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses

Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation

Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor